A Study to Investigate the Safety and Efficacy of Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

Trial Profile

A Study to Investigate the Safety and Efficacy of Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

Completed
Phase of Trial: Phase II

Latest Information Update: 11 May 2010

At a glance

  • Drugs Asvasiran sodium (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GEMINI
  • Most Recent Events

    • 11 May 2010 Results have been published in the Proceedings of the National Academy of Sciences of the United States of America.
    • 28 Apr 2010 Results reported by Alnylam Pharmaceuticals.
    • 14 Feb 2008 The expected completion date for this trial is now 1 Nov 2007 as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top